Editor's Picks

There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.

Schering Plough Corp

Schering Plough Corp

  1. Healthcare deals are still out there
    The Deal: Blogs 7 hours ago

    There was tremendous consolidation in healthcare during the first three quarters. Full Article at The Deal: Blogs

  2. Schering-Plough Corp-Financial Company Report - research report released
    PR-Inside.com logo PR-Inside.com 23 hours ago

    2009-12-07 04:32:42 - total common shares outstanding. Finally the report includes quarterly book value per share vs. share price. Much of the information contained in the report is included in both tabular and graphic formats. Full Article at PR-Inside.com

  3. AP Photo logo AP Photo 4 months ago
    FILE - In this 2004 file photo provided by Schering-Plough Corp. , the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co. , and Schering-Plough Corp. , is shown.

    FILE - In this 2004 file photo provided by Schering-Plough Corp. , the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co. , and Schering-Plough Corp. , is shown. View Photo »

  4. We are pleased that Schering-Plough HealthCare Products has achieved this significant regulatory milestone for ZEGERID OTC and we look forward to seeing the product on retail store shelves across the United States in the first half of 2010
    SOURCE: Medical News Today 5 days ago
  5. Merck & Co. Receives FDA Approval For Zegerid OTC
    Pharmaceutical Business Review 3 days ago

    Merck & Co. has received FDA approval for Zegerid OTC (omeprazole 20mg/sodium bicarbonate 1100mg capsules), for over-the-counter treatment of frequent heartburn. Full Article at Pharmaceutical Business Review

  6. Michael Loucks And Pharma Fraud: What Next?
    Pharmalot 4 days ago

    By now, you probably have heard that Michael Loucks is leaving the US Attorney’s office in Boston, where he spent nearly 25 years and was the most visible and arguably influential prosecutor of health care fraud, especially fraud involving... Full Article at Pharmalot

  7. Stock Picks: SNTS Up; WAG Down (Market Movers)
    Smartmoney.com logo Smartmoney.com 5 days ago

    Shares of the biopharmaceutical company Santarus (SNTS) jumped as much as 30% in early trading, although the spike had moderated a bit by midmorning, after the company announced FDA approval for an over-the-counter dose of the heartburn medication... Full Article at Smartmoney.com

  8. AP Photo logo AP Photo 9 months ago
    In this Sept. 6, 2006 file photo, Schering-Plough Corp. , headquarters in Kenilworth, N.J. , is seen.

    In this Sept. 6, 2006 file photo, Schering-Plough Corp. , headquarters in Kenilworth, N.J. , is seen. View Photo »

  9. Increasing pressures on the pharmaceutical industry and Schering-Plough, particularly in the United States, and the need to reduce costs and increase efficiencies through a more streamlined work force.
    SOURCE: InPharmaTechnologist 1 week ago
  10. The New York Yankees' Mark Teixeira, Schering-Plough Corpora
    YouTube Logo YouTube Videos 5 months ago
  11. FDA Approves Merck & Co., Inc.'s ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn Unique Dual-Ingredient Formulation Available for 24-Hour Frequent Heartburn Relief Without A Prescription
    Biospace logo Biospace 5 days ago

    WHITEHOUSE STATION, N.J. , Dec. 1 /PRNewswire/ -- Merck & Co. , Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of... Full Article at Biospace

  12. Santarus (NASDAQ:SNTS) Strikes 52-week High Stocks after FDA Approval
    TransWorldNews logo TransWorldNews 5 days ago

    Santarus, Inc. (NASDAQ:SNTS) soared 30.54% to $5.60 in the opening session after hitting a 52-week high at $5.70. Full Article at TransWorldNews

(What's this?)
  1. Are you a Publisher?

    We built Daylife.com using our SmartMedia Services platform, which can give you thousands of content-rich, advertiser-friendly pages (like this one) on any topic and with full editorial control. Learn More »

    Our Customers
    prev
    next
  2. Our Products
    Daylife Select

    A point & click tool to create dynamic content portals. Learn More »

  3. Daylife API

    Unlimited smart, customizable content to suit any publisher. Learn More »

  4. Enterprise API

    Use the Daylife Platform to distribute content across your sites. Learn More »

  5. SmartContext

    Weave the web's best content into your own. Learn More »

About Schering Plough Corp

Wikipedia

There are no results for this module. Edit this module to change the search term used to query Wikipedia

Related Photos

In this Sept. 6, 2006 file photo, Schering-Plough Corp. , headquarters in Kenilworth, N.J. , is seen.
Pause Play 1/25
prev
  1. FILE - In this 2004 file photo provided by Schering-Plough Corp. , the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co. , and Schering-Plough Corp. , is shown. AP Photo logo AP Photo 4 months ago

    FILE - In this 2004 file photo provided by Schering-Plough Corp. , the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co. , and Schering-Plough Corp. , is shown.

    View Photo »
  2. In this Sept. 6, 2006 file photo, Schering-Plough Corp. , headquarters in Kenilworth, N.J. , is seen. AP Photo logo AP Photo 9 months ago

    In this Sept. 6, 2006 file photo, Schering-Plough Corp. , headquarters in Kenilworth, N.J. , is seen.

    View Photo »
  3. A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. �EUTERS/Jeff Zelevansky. Reuters Pictures 9 months ago

    A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. �EUTERS/Jeff Zelevansky.

    View Photo »
  4. A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. Reuters Pictures 9 months ago

    A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.

    View Photo »
  5. File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters. AP Photo logo AP Photo 4 months ago

    File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.

    View Photo »
  6. File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters. AP Photo logo AP Photo 4 months ago

    File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.

    View Photo »
  7. File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters. AP Photo logo AP Photo 4 months ago

    File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.

    View Photo »
  8. In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters. AP Photo logo AP Photo 4 months ago

    In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.

    View Photo »
  9. In this Jan. 26, 2006 file photo, Richard Clark, CEO of Merck, USA, addresses a panel session on corporate heads after their first 100 days during the World Economic Forum WEF in Davos, Switzerland. AP Photo logo AP Photo 9 months ago

    In this Jan. 26, 2006 file photo, Richard Clark, CEO of Merck, USA, addresses a panel session on corporate heads after their first 100 days during the World Economic Forum WEF in Davos, Switzerland.

    View Photo »
  10. In this May 22, 2008 file photo, Merck & Co. headquarters is seen in Whitehouse Station, N.J. Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash, Monday, March 9, 2009, in a deal that gives the companies more firepower to compete in a drug industry facing s... AP Photo logo AP Photo 9 months ago

    In this May 22, 2008 file photo, Merck & Co. headquarters is seen in Whitehouse Station, N.J. Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash, Monday, March 9, 2009, in a deal that gives the companies more firepower to compete in a drug industry facing s...

    View Photo »
  11. Graphic shows product sales figures for Merck & co. and Schering-Plough Corp. 1c x 5 1/4 inches; 46.5 mm x 133 mm;. AP Photo logo AP Photo 9 months ago

    Graphic shows product sales figures for Merck & co. and Schering-Plough Corp. 1c x 5 1/4 inches; 46.5 mm x 133 mm;.

    View Photo »
  12. A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. �EUTERS/Jeff Zelevansky. Reuters Pictures 9 months ago

    A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. �EUTERS/Jeff Zelevansky.

    View Photo »
  13. A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. Reuters Pictures 9 months ago

    A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.

    View Photo »
  14. A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. Reuters Pictures 9 months ago

    A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.

    View Photo »
  15. A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. Reuters Pictures 9 months ago

    A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.

    View Photo »
  16. A sample of the drug Singulair made by Merk & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. Reuters Pictures 9 months ago

    A sample of the drug Singulair made by Merk & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks.

    View Photo »
  17. A sample of the drug Singulair made by Merk & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. Reuters Pictures 9 months ago

    A sample of the drug Singulair made by Merk & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks.

    View Photo »
  18. A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. Reuters Pictures 9 months ago

    A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks.

    View Photo »
  19. A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. Reuters Pictures 9 months ago

    A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks.

    View Photo »
  20. A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. Reuters Pictures 9 months ago

    A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks.

    View Photo »
  21. A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. Reuters Pictures 9 months ago

    A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks.

    View Photo »
  22. Richard Clark, Chairman and C.E.O. of Merck, is shown in this undated handout image released by Merck on March 9, 2009. Reuters Pictures 9 months ago

    Richard Clark, Chairman and C.E.O. of Merck, is shown in this undated handout image released by Merck on March 9, 2009.

    View Photo »
  23. This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Vytorin. Reuters Pictures 9 months ago

    This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Vytorin.

    View Photo »
  24. This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Zetia. Reuters Pictures 9 months ago

    This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Zetia.

    View Photo »
  25. Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file photo taken November 19, 2008. Reuters Pictures 9 months ago

    Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file photo taken November 19, 2008.

    View Photo »
next
AP Photo logo AP Photo 9 months ago

In this Sept. 6, 2006 file photo, Schering-Plough Corp. , headquarters in Kenilworth, N.J. , is seen.

View Photo »
View All »

Related Topics

  1. Merck & Company, Inc. Merck & Company, Inc.
  2. Pfizer Inc. Pfizer Inc.
  3. US Food and Drug Administration US Food and Drug Administration
  4. Diabetes Diabetes
  5. Food and Drug Administration Food and Drug Administration
  6. Lipitor

Timeline of Coverage

  1. Click to see all coverage from Oct 21, 2009
    36
    October 21, 2009
  2. Click to see all coverage from Oct 22, 2009
    92
    October 22, 2009
  3. Click to see all coverage from Oct 23, 2009
    78
    October 23, 2009
  4. Click to see all coverage from Oct 24, 2009
    1
    October 24, 2009
  5. Click to see all coverage from Oct 25, 2009
    5
    October 25, 2009
  6. Click to see all coverage from Oct 26, 2009
    7
    October 26, 2009
  7. Click to see all coverage from Oct 27, 2009
    8
    October 27, 2009
  8. Click to see all coverage from Oct 28, 2009
    7
    October 28, 2009
  9. Click to see all coverage from Oct 29, 2009
    34
    October 29, 2009
  10. Click to see all coverage from Oct 30, 2009
    24
    October 30, 2009
  11. Click to see all coverage from Oct 31, 2009
    4
    October 31, 2009
  12. Click to see all coverage from Nov 01, 2009
    4
    November 01, 2009
  13. Click to see all coverage from Nov 02, 2009
    65
    November 02, 2009
  14. Click to see all coverage from Nov 03, 2009
    40
    November 03, 2009
  15. Click to see all coverage from Nov 04, 2009
    93
    November 04, 2009
  16. Click to see all coverage from Nov 05, 2009
    20
    November 05, 2009
  17. Click to see all coverage from Nov 06, 2009
    7
    November 06, 2009
  18. Click to see all coverage from Nov 07, 2009
    1
    November 07, 2009
  19. Click to see all coverage from Nov 08, 2009
    2
    November 08, 2009
  20. Click to see all coverage from Nov 09, 2009
    10
    November 09, 2009
  21. Click to see all coverage from Nov 10, 2009
    9
    November 10, 2009
  22. Click to see all coverage from Nov 11, 2009
    7
    November 11, 2009
  23. Click to see all coverage from Nov 12, 2009
    14
    November 12, 2009
  24. Click to see all coverage from Nov 13, 2009
    16
    November 13, 2009
  25. Click to see all coverage from Nov 14, 2009
    3
    November 14, 2009
  26. Click to see all coverage from Nov 15, 2009
    24
    November 15, 2009
  27. Click to see all coverage from Nov 16, 2009
    65
    November 16, 2009
  28. Click to see all coverage from Nov 17, 2009
    13
    November 17, 2009
  29. Click to see all coverage from Nov 18, 2009
    14
    November 18, 2009
  30. Click to see all coverage from Nov 19, 2009
    17
    November 19, 2009
  31. Click to see all coverage from Nov 20, 2009
    13
    November 20, 2009
  32. Click to see all coverage from Nov 21, 2009
    2
    November 21, 2009
  33. Click to see all coverage from Nov 22, 2009
    2
    November 22, 2009
  34. Click to see all coverage from Nov 23, 2009
    2
    November 23, 2009
  35. Click to see all coverage from Nov 24, 2009
    14
    November 24, 2009
  36. Click to see all coverage from Nov 25, 2009
    4
    November 25, 2009
  37. Click to see all coverage from Nov 26, 2009
    0
    November 26, 2009
  38. Click to see all coverage from Nov 27, 2009
    0
    November 27, 2009
  39. Click to see all coverage from Nov 28, 2009
    0
    November 28, 2009
  40. Click to see all coverage from Nov 29, 2009
    0
    November 29, 2009
  41. Click to see all coverage from Nov 30, 2009
    11
    November 30, 2009
  42. Click to see all coverage from Dec 01, 2009
    16
    December 01, 2009
  43. Click to see all coverage from Dec 02, 2009
    30
    December 02, 2009
  44. Click to see all coverage from Dec 03, 2009
    1
    December 03, 2009
  45. Click to see all coverage from Dec 04, 2009
    2
    December 04, 2009
  46. Click to see all coverage from Dec 05, 2009
    2
    December 05, 2009
  47. Click to see all coverage from Dec 06, 2009
    0
    December 06, 2009
  48. Click to see all coverage from Dec 07, 2009
    4
    December 07, 2009

Related Videos

  1. YouTube
  2. Videosurf
  3. Truveo
  1. Loading video...
    1. Watch video
      Nomad Stories Fred Hassan, Schering-Plough Corp
      13 months ago
    2. Watch video
      The New York Yankees' Mark Teixeira, Schering-P...
      5 months ago
    3. Watch video
      SCHERING-PLOUGH INTRODUCES AFRIN® PURESEA™:...
      9 months ago
    4. Watch video
      The New York Yankees' Mark Teixeira, Schering-P...
      5 months ago
    5. Watch video
      Merck Buying Schering-Plough in $41.1B Deal
      9 months ago
    6. Watch video
      The New York Yankees' Mark Teixeira, Schering-P...
      5 months ago
    View All YouTube Videos »
    1. Watch video
      Nomad Stories Fred Hassan, Schering-Plough Corp
      13 months ago
    2. Watch video
      Merck to buy Schering-Plough in $41.1 bn deal
      9 months ago
    3. Watch video
      Anti-Cholesterol Drug Flunks Tests
      23 months ago
    4. Watch video
      Technical Analysis Review of the Stock Market 8...
      40 months ago
    5. Watch video
      Technical Analysis Review of the Stock Market 8...
      40 months ago
    6. Watch video
      Technical Analysis Stock Trading Ideas for 8/3/...
      40 months ago
    View All Videosurf Videos »
  3. Powered by Truveo
    1. Watch video
      Conover Favors Schering on Fewer Patent Expirat...
      16 months ago
    2. Watch video
      U.S. Stocks Rise as Merck, Schering Lead Drugm...
      10 months ago
    3. Watch video
      Jeffrey Saut Calls JPMorgan's Bear Purchase `Br...
      21 months ago
    4. Watch video
      U.S. Stocks Decline as Oil Rebounds, Drugmakers...
      16 months ago
    5. Watch video
      Anti-Cholesterol Drug Flunks Tests
      23 months ago
    6. Watch video
      Monday : Merck Schering Deal [03-09-09 12:05 PM]
      9 months ago
    View All Truveo Videos »

Related Quotes

  • Previous
  • Next
  • 1/13
  1. We are pleased that Schering-Plough HealthCare Products has achieved this significant regulatory milestone for ZEGERID OTC and we look forward to seeing the product on retail store shelves across the United States in the first half of 2010
    SOURCE: Medical News Today 5 days ago
  2. Increasing pressures on the pharmaceutical industry and Schering-Plough, particularly in the United States, and the need to reduce costs and increase efficiencies through a more streamlined work force.
    SOURCE: InPharmaTechnologist 1 week ago
  3. The combination of the considerable talents of Schering-Plough and Merck employees across the globe positions Merck to move through this dynamic time for our industry with a clear vision for the future.
    SOURCE: Middle East North Africa Financial Network 1 month ago
  4. Our company has a commitment to reducing the prevalence of rabies in vulnerable places around the world, and these new initiatives in India demonstrate continuing support of eradication efforts ... As with the Afya Serengeti project that Schering-Plough supports in Africa, educating people about rabies ...
    SOURCE: Freshnews.com 1 month ago
  5. The consent order announced today addresses the competitive concerns related to Schering-Plough's proposed acquisition of Merck
    SOURCE: Reuters 1 month ago
  6. Approval from the European Commission marks a key milestone for the completion of our transaction with Schering-Plough
    SOURCE: Drugs.com 1 month ago
  7. This quarter we delivered operational top-line growth, reconciled bottom-line growth and major pipeline successes. We powered through - even in the face of tough global economic and currency headwinds ... As we near the anticipated close of our combination with Merck, we are proud of how our colleagues ...
    SOURCE: Street Insider 1 month ago
  8. We are pleased to acquire these assets from Schering-Plough
    SOURCE: PR-Inside.com 1 month ago
  9. By the summer of 2005, [Schering-Plough/Merck’s] marketing division [was] so successful that [VYTORIN was] already a blockbuster drug. There was only downside [to analyzing the results of ENHANCE trial].
    SOURCE: PharmaGossip 1 month ago
  10. With this approval, Schering-Plough can now bring SIMPONI, one of the five stars in our development pipeline, to market in Europe
    SOURCE: Freshnews.com 2 months ago
  11. With this approval, Schering-Plough can now bring Simponi, in our development pipeline, to market in Europe. Offering once-monthly subcutaneous dosing, Simponi will provide an important and convenient new treatment option to rheumatologists and their patients.
    SOURCE: Pharmaceutical Business Review 2 months ago
  12. Investissement Quebec provided a $3 million grant and this was very important in Schering-Plough Corp. choosing Quebec for this facility, among many other possible locations around the world.
    SOURCE: Canoe 2 months ago
  13. The sale of Merck's interest in Merial allows us to remain on track for the closing of our merger with Schering-Plough in the fourth quarter, as planned
    SOURCE: ReadingEagle.com 2 months ago
View All »